140 related articles for article (PubMed ID: 22799290)
1. The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact.
Ng CH; Pathy NB; Taib NA; Mun KS; Rhodes A; Yip CH
Asian Pac J Cancer Prev; 2012; 13(4):1111-3. PubMed ID: 22799290
[TBL] [Abstract][Full Text] [Related]
2. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
[TBL] [Abstract][Full Text] [Related]
3. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
6. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
7. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
8. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
14. Expression of DDR1 and DVL1 in invasive ductal and lobular breast carcinoma does not correlate with histological type, grade and hormone receptor status.
Ameli F; Rose IM; Masir N
Asian Pac J Cancer Prev; 2015; 16(6):2385-90. PubMed ID: 25824769
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
[TBL] [Abstract][Full Text] [Related]
17. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
19. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of hormone receptor status in 5758 Chinese females with breast cancer].
Gao JD; Wang J; Feng XL; Zhong YX; Wang X
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):683-6. PubMed ID: 20021865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
